IL-31 RA Molekülinformation
Molecule Name
Interleukin-31 receptor subunit alpha
Molekülalias
IL-31 RA,IL-31RA,hGLM-R,CRL3,GPL,ZcytoR17,GLM-R,IL-31R-alpha,Gp130-like receptor
Drug Development Progress
Anzahl der klinischen Arzneimittel0
Anzahl der inverkehr gebrachten Arzneimittel1
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
GLM-R，CRL，IL-31R subunit alpha，IL-31 receptor subunit alpha，Cytokine receptor-like 3，Gp130-like monocyte receptor，IL-31RA，ZcytoR17，IL-31R-alpha，PRO21384，GPL，CRL3，GLMR，Interleukin 31 Receptor A，Soluble Type I Cytokine Receptor CRL3，PLCA2，Class I Cytokine Receptor，hGLM-R，Gp130-like receptor
Molekülhintergrund
Interleukin-31 receptor subunit alpha is a protein that in humans is encoded by the IL31RA gene, also known as IL-31 receptor subunit alpha, IL-31RA, GLM-R, Gp130-like receptor, CRL3, GPL. Oncostatin M receptor (OSMR) and IL31RA form the heterodimeric receptor through which IL31 signals. IL31RA is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. dditionally, demonstrate Jak1 binding to GPL and its activation in heteromeric complexes with the OSMRbeta but also in a homomeric receptor complex.
IL-31 RA Produktliste
You Have Viewed 0 Of 0 Results
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Nemolizumab | CD-14152; CIM-331; M 5250; M 5250B | Approved | Chugai Pharmaceutical Co Ltd | Mitchga, Nemluvio | Japan | Dermatitis, Atopic; Pruritus | Maruho Co Ltd | 2022-03-28 | Dermatitis, Atopic; Prurigo; Prurigo Nodularis; Pruritus; Scleroderma, Systemic | Details |